Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones
Disc Medicine 宣布与 Mabwell Therapeutics 签订独家许可协议，开发用于调节铁稳态的新型抗tmprSS6单克隆抗体；Mabwell将获得1000万美元的预付款和高达4.125亿美元的里程碑收入
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones
Disc Medicine公司宣布与Mabwell Treeutics公司就新型抗TMPRSS6单抗达成独家许可协议，以调节铁稳态；Mabwell公司将获得1000万美元的预付款和高达4.125亿美元的里程碑